Safety review of antithrombotic therapy options after left atrial appendage occlusion

Area of Science:

• Cardiology
• Interventional Cardiology
• Thrombosis Management

Background:

• Left atrial appendage occlusion (LAAO) offers an alternative to oral anticoagulation for non-valvular atrial fibrillation (NVAF) patients intolerant to anticoagulants.
• Current post-LAAO antithrombotic strategies are largely consensus-based, with patients typically receiving oral anticoagulation followed by antiplatelet agents.
• Patient tolerance to standard antithrombotic regimens varies, necessitating exploration of alternative therapeutic options.

Purpose of the Study:

• To review the safety and efficacy profiles of various antithrombotic therapy options following LAAO.
• To compare the incidence of device-related thrombosis (DRT), bleeding, and thromboembolic events across different antithrombotic regimens.
• To summarize current evidence from randomized controlled trials and meta-analyses regarding antithrombotic combinations and duration.

Main Methods:

• Comprehensive review of recent randomized controlled trials and meta-analyses.
• Analysis of safety profiles, including device-related thrombosis, bleeding events, and thromboembolic outcomes.
• Comparison of direct oral anticoagulants (DOACs), vitamin K antagonists (VKAs), single antiplatelet therapy (SAPT), and dual antiplatelet therapy (DAPT).

Main Results:

• Initial post-LAAO antithrombotic monotherapy with DOACs is associated with low rates of thromboembolism, DRT, and major bleeding.
• Dual antiplatelet therapy (DAPT) demonstrates a lower incidence of thromboembolic events compared to single antiplatelet therapy (SAPT).
• The combination of DOACs with antiplatelet therapy requires careful consideration of bleeding risks versus thromboembolic protection.

Conclusions:

• DOAC monotherapy appears to be a safe and effective initial strategy post-LAAO, offering a favorable balance of risks.
• DAPT provides superior protection against thromboembolic events compared to SAPT following LAAO.
• Personalized antithrombotic strategies, considering patient-specific factors and team-patient discussions, are crucial for optimal outcomes after LAAO.